SCHEMBL25218322

SCHEMBL25218322

Cn1c(N2C[C@H](F)C[C@@H](Nc3ncc(C(F)(F)F)cn3)C2)nc2cc([N+](=O)[O-])c(Cl)cc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.34
FGFR4 P22455 1/20 0.34
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
MAPT P10636 4/20 0.33
TDP1 Q9NUW8 2/20 0.32
EGFR P00533 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
GAA P10253 2/20 0.31
NPC1 O15118 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
CASP3 P42574 1/20 0.31
RAB9A P51151 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
PGK1 P00558 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25285585 1.00 CHRM4 (0.34) CHRM4FGFR4MEN1KMT2AMAPT
SCHEMBL25279915 1.00 CHRM4 (0.34) CHRM4FGFR4MEN1KMT2AMAPT
SCHEMBL25220796 0.92 PKM (0.32) CHRM4MAPTPKMMETMAPK1
SCHEMBL25275778 0.92 PKM (0.32) CHRM4MAPTPKMMETMAPK1
SCHEMBL25279111 0.91 IL1B (0.33) CHRM4FGFR4MEN1KMT2APKM
SCHEMBL30464446 0.91 IL1B (0.33) CHRM4FGFR4MEN1KMT2APKM
SCHEMBL25222644 0.91 IL1B (0.33) CHRM4FGFR4MEN1KMT2APKM
SCHEMBL25263303 0.88 SERPINE1 (0.36) MEN1KMT2AMAPTSMN1; SMN2CYP1A2
SCHEMBL25268511 0.88 GRM6 (0.33) MEN1KMT2AMAPTTDP1
SCHEMBL30534009 0.88 GRM6 (0.33) MEN1KMT2AMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS INCYTE CORPORATION 2023-06-29 US disclosed
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS INCYTE CORPORATION 2023-06-29 US disclosed
WO-2023102184-A1 BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203010-A1 BICYCLIC AMINE CDK12 INHIBITORS CDK12, CDK1, CDK2 CHRM4 4533/4885FGFR4 1564/4885MEN1 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.